A
Ashwin Gollerkeri
Researcher at Bristol-Myers Squibb
Publications - 16
Citations - 1285
Ashwin Gollerkeri is an academic researcher from Bristol-Myers Squibb. The author has contributed to research in topics: Dasatinib & Imatinib mesylate. The author has an hindex of 10, co-authored 11 publications receiving 1252 citations.
Papers
More filters
Journal ArticleDOI
Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
Jorge E. Cortes,Philippe Rousselot,Dong-Wook Kim,Ellen K. Ritchie,Nelson Hamerschlak,Steven Coutre,Andreas Hochhaus,François Guilhot,Giuseppe Saglio,Jane F. Apperley,Oliver G. Ottmann,Neil P. Shah,Philipp Erben,Susan Branford,Prasheen Agarwal,Ashwin Gollerkeri,Michele Baccarani +16 more
TL;DR: Dasatinib is highly active and produces hematologic and cytogenetic responses in a significant number of patients with imatinib-resistant or -intolerant MBC- and LBC-CML.
Journal ArticleDOI
Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase.
François Guilhot,Jane F. Apperley,Dong-Wook Kim,Eduardo Bullorsky,Michele Baccarani,Gail J. Roboz,Sergio Amadori,Carmino Antonio De Souza,Jeffrey H. Lipton,Andreas Hochhaus,Dominik Heim,Richard A. Larson,Susan Branford,Martin C. Müller,Prasheen Agarwal,Ashwin Gollerkeri,Moshe Talpaz +16 more
TL;DR: Dasatinib as discussed by the authors is a novel, potent, oral, multitargeted kinase inhibitor of BCR-ABL and SRC-family kinases that showed marked efficacy in a phase 1 trial of patients with imatinib-resistant CML.
Journal ArticleDOI
Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome–positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study
Oliver G. Ottmann,Hervé Dombret,Giovanni Martinelli,Bengt Simonsson,François Guilhot,Richard A. Larson,Giovanna Rege-Cambrin,Jerald P. Radich,Andreas Hochhaus,A. Apanovitch,Ashwin Gollerkeri,Steven Coutre +11 more
TL;DR: Dasatinib represents a safe and effective treatment option and an important therapeutic advance for patients with Ph-positive ALL and most adverse events were grade 1 or 2; febrile neutropenia was the most frequent severe AE, but this and other cytopenias were manageable with dose reduction.
Journal ArticleDOI
Dasatanib (D) in patients (pts) with chronic myelogenous leukemia (CML) in lymphoid blast crisis (LB-CML) or Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ALL) who are imatinib (IM)-resistant (IM-R) or intolerant (IM-I): The CA180015 'START-L' study
Steven Coutre,Giovanni Martinelli,Hervé Dombret,A. Hochhaus,Richard A. Larson,G. Saglio,Ashwin Gollerkeri,A. Apanovitch,O. G. Ottman +8 more
TL;DR: D is active in IM pretreated LB-CML and Ph+ALL pts, and grade 3-4 thrombocytopenia and neutropenia was seen in 82% and 76%, respectively.
Journal ArticleDOI
Dasatinib (SPRYCEL®) in Patients (pts) with Chronic Myelogenous Leukemia in Accelerated Phase (AP-CML) That Is Imatinib-Resistant (im-r) or -Intolerant (im-i): Updated Results of the CA180–005 ’START-A’ Phase II Study.
Jorge E. Cortes,Dong-Kee Kim,François Guilhot,Giovanni Rosti,Richard T. Silver,Ashwin Gollerkeri,Prasheen Agarwal,Susan Branford,J. F. Apperley +8 more
TL;DR: Dasatinib is highly effective in pts with im-r or im-i AP-CML with high rates of durable MaHR and MCyR, and an updated analysis with at least 12 months of follow-up will be presented.